How nanotechnology can enhance docetaxel therapy

Zhang, Li; Zhang, Na

doi:10.2147/ijn.s46921

Cited by 99 publications

(60 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, cumulative literature demonstrates that drug nanoformulations can reverse drug resistance. Therefore, we believe that Dtxl-based nanomedicine can provide a novel way to deliver docetaxel in its active form to cancer cells and redefine the drug interaction [10, 11]. About 388 studies report improved Dtxl therapeutic activity using various forms of nanoparticles (PubMed search conducted on Dec. 30, 2015).…”

Section: Introductionmentioning

confidence: 99%

PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer

Nagesh

Johnson

Boya

et al. 2016

Colloids and Surfaces B: Biointerfaces

110

View full text Add to dashboard Cite

Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was to develop and determine the anti-cancer efficacy of a novel docetaxel loaded, prostate specific membrane antigen (PSMA) targeted superparamagnetic iron oxide nanoparticle (SPION) (J591-SPION-Dtxl) formulation for PC therapy. Our results showed the SPION-Dtxl formulation exhibits an optimal particle size and zeta potential, which can efficiently be internalized in PC cells. SPION-Dtxl exhibited potent anti-cancer efficacy via induction of the expression of apoptosis associated proteins, downregulation of anti-apoptotic proteins, and inhibition of chemo-resistance associated protein in PC cell lines. J591-SPION-Dtxl exhibited a profound uptake in C4-2 (PSMA+) cells compared to PC-3 (PSMA−) cells. A similar targeting potential was observed in ex-vivo studies in C4-2 tumors but not in PC-3 tumors, suggesting its tumor specific targeting. Overall this study suggests that a PSMA antibody functionalized SPION-Dtxl formulation can be highly useful for targeted PC therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer

Nagesh

Johnson

Boya

et al. 2016

Colloids and Surfaces B: Biointerfaces

110

View full text Add to dashboard Cite

show abstract

“…By targeting multiple genes, such as Bcl-2, cyclin D1 and silent information regulator 1, miRNA-34a is able to suppress tumor angiogenesis, induce cancer cell apoptosis, block proliferation, revert the EMT, and thereby inhibit tumor growth121314. Docetaxel (DTX) is a broad-spectrum chemotherapeutic drug that possesses strong activity against many human cancers, such as metastatic breast, lung, prostate and ovarian cancers, through its binding to β-tubulin and stabilizing microtubules, thus leading to cell cycle arrest and cell apoptosis15. However, the clinical application of DTX is greatly limited by its poor water-solubility, rapid clearance rate, adverse side effects, poor tumor penetration and the occurrence of drug resistance1617.…”

mentioning

confidence: 99%

Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer

Zhang

Yang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Co-delivery of microRNAs and chemotherapeutic drugs into tumor cells is an attractive strategy for synergetic breast cancer therapy due to their complementary mechanisms. In this work, a core-shell nanocarrier coated by cationic albumin was developed to simultaneously deliver miRNA-34a and docetaxel (DTX) into breast cancer cells for improved therapeutic effect. The co-delivery nanocarriers showed a spherical morphology with an average particle size of 183.9 nm, and they efficiently protected miRNA-34a from degradation by RNase and serum. Importantly, the nanocarriers entered the cytosol via a caveolae-mediated pathway without entrapment in endosomes/lysosomes, thus improving the utilization of the cargo. In vitro, the co-delivery nanocarriers suppressed the expression of anti-apoptosis gene Bcl-2 at both transcription and protein levels, inhibited tumor cell migration and efficiently induced cell apoptosis and cytotoxicity. In vivo, the co-delivery nanocarriers prolonged the blood circulation of DTX, enhanced tumor accumulation of the cargo and significantly inhibited tumor growth and metastasis in 4T1-tumor bearing mice models. Taken together, the present nanocarrier co-loading with DTX and miRNA-34a is a new nanoplatform for the combination of insoluble drugs and gene/protein drugs and provides a promising strategy for the treatment of metastatic breast cancer.

show abstract

“…Dendrimers can be prepared for the delivery of both hydrophobic and hydrophilic drugs, nucleic acids, and imaging agents due to their attractive properties such as well-defined size and molecular weight, monodispersity, multivalency, number of available internal cavities, high degree of branching, and high number of surface functional groups [10, 28–30]. Several literature sources demonstrate the ability of dendrimer targeting ligands to induce the specific targeting and destruction of tumours.…”

Section: Chemicophysical Characteristics Of Nanoparticles Employedmentioning

confidence: 99%

Drug Delivery Nanoparticles in Skin Cancers

Dianzani

Zara

Maina

et al. 2014

BioMed Research International

139

111

View full text Add to dashboard Cite

Nanotechnology involves the engineering of functional systems at nanoscale, thus being attractive for disciplines ranging from materials science to biomedicine. One of the most active research areas of the nanotechnology is nanomedicine, which applies nanotechnology to highly specific medical interventions for prevention, diagnosis, and treatment of diseases, including cancer disease. Over the past two decades, the rapid developments in nanotechnology have allowed the incorporation of multiple therapeutic, sensing, and targeting agents into nanoparticles, for detection, prevention, and treatment of cancer diseases. Nanoparticles offer many advantages as drug carrier systems since they can improve the solubility of poorly water-soluble drugs, modify pharmacokinetics, increase drug half-life by reducing immunogenicity, improve bioavailability, and diminish drug metabolism. They can also enable a tunable release of therapeutic compounds and the simultaneous delivery of two or more drugs for combination therapy. In this review, we discuss the recent advances in the use of different types of nanoparticles for systemic and topical drug delivery in the treatment of skin cancer. In particular, the progress in the treatment with nanocarriers of basal cell carcinoma, squamous cell carcinoma, and melanoma has been reported.

show abstract

How nanotechnology can enhance docetaxel therapy

Cited by 99 publications

References 136 publications

PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer

PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer

Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer

Drug Delivery Nanoparticles in Skin Cancers

Contact Info

Product

Resources

About